Skip to main content
Cancer Control: Journal of the Moffitt Cancer Center logoLink to Cancer Control: Journal of the Moffitt Cancer Center
. 2024 Apr 29;31:10732748241249896. doi: 10.1177/10732748241249896

Role of Insulin Use and Social Determinants of Health on Non-melanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System

Nour Massouh 1,2, Ayad A Jaffa 2,3,, Miran A Jaffa 1,
PMCID: PMC11075616  PMID: 38680117

Abstract

Background

Non-melanoma skin cancer (NMSC) is a frequent type of malignancy with a steadily increasing incidence rate worldwide. Although NMSC was shown to be associated with diabetes, no studies have addressed the extent to which insulin use influences the risk of NMSC in light of social determinants of health (SDOH). We conducted a quantitative study that examined the interplay between insulin use, SDOH, additional covariates, and NMSC among individuals with diabetes.

Methods

We based our analysis on the 2020 Behavioral Risk Factor Surveillance System (BRFSS), a national survey conducted yearly in the US. We performed weighted chi-squared test, logistic regression, and survival analyses on 8685 eligible participants with diabetes enrolled in the BRFSS.

Results

Kaplan Meier survival curves showed higher probability of NMSC event-free survival for participants with diabetes using insulin compared to participants with diabetes not using insulin (log-rank test P < .001). Significant associations were detected between insulin use and reduced odds of NMSC (OR .56; 95% CI: .38-.82), and decreased hazard (HR .36; 95% CI: .21-.62), along with indices of SDOH.

Conclusions

Our findings suggest that socioeconomic differences related to the healthcare system and behavioral patterns are linked to discrepancies in the use of insulin and the development of NMSC.

Keywords: behavioral risk factor surveillance system, diabetes, health inequity, insulin use, non-melanoma skin cancer, social determinants of health

Background

Non-melanoma skin cancer (NMSC) is the most common human malignancy 1 that was marked over the past decades by a substantial worldwide increase in incidence and morbidity, as well as associated cost of treatment.2-4 This type of skin cancer manifests in the form of a lump or discolored patch that develops slowly in the upper layers of the skin and presents mostly on sun-exposed skin. 5 According to the World Health Organization (WHO), approximately 2 to 3 million new cases of NMSC are diagnosed each year globally, 6 and in North America, this disease is characterized as being one of the most prevalent types of cancer7,8 particularly among the aging population of White males.8-10 The observed steady increase in its prevalence 11 and incidence rate 9 over the last 3 decades marked NMSC as an important public health problem that is of global concern.

The primary risk factors for NMSC include fair skin, a history of sun damage, and extensive exposure to Ultraviolet (UV) radiation, particularly Ultraviolet B (UVB) radiation. 7 Moreover, according to the Global Burden of Disease Study (1990-2017), with increasing age, the Disability-Adjusted Life Years (DALYs) for NMSC increase exponentially. 9 The incidence of NMSC is also generally found higher in men than in women. 10 Furthermore, results from meta-analyses suggest an association between BMI and NMSC, and between alcohol consumption and increased risk of NMSC.12,13 Finally, while smoking has been consistently identified as a risk factor for several types of cancer,14,15 there is evidence that current smoking is associated with a decreased risk of NSMC.16,17

Diabetes is a chronic health condition marked by elevated levels of glucose in the blood, and over time, it can lead to severe systemic complications that cause considerable morbidity and mortality. 18 It has also become a burden on the socioeconomic system, 11 thus emerging as a public health threat. Few studies have shown an association between diabetes and the development of certain cancers, 19 including NMSC.20,21 A retrospective cohort study in Taiwan found that participants with diabetes aged 60 or older had an increased risk of NMSC, 20 while record linkage studies in England found that hospitalization for diabetes was associated with an increased risk of several types of cancer, including NMSC. 21 A number of observational randomized trials were performed to determine if insulin therapy could be associated with increased risk of cancer in individuals with diabetes.22-24 The outcome of the results were inconsistent, some reporting that insulin therapy is associated with increased risk of cancer while others showed no relevance to cancer risk.22-24 The conflicting results of existing studies could reflect the biological diversity of cancer. In general, the data from epidemiological studies negate the effects of insulin therapy on cancer risk in individuals with type 2 diabetes. The only trial that showed a link between insulin therapy and increased cancer mortality is the DIGAMI study, whereas all the other studies including the ORIGIN trial did not observe any increase in cancer risk in specific types that include lung, breast, prostate, colorectal or melanoma.25,26 In addition, there is limited information regarding the association between anti-diabetic drugs or therapies and NMSC. A reduced risk of developing NMSC among individuals with type 2 diabetes using anti-diabetic medications, such as sodium-glucose co-transporter-2 (SGLT-2) inhibitors, Rosiglitazone, and Metformin was reported,27-29 but there is a paucity of data specifically addressing the association between insulin use therapy and NMSC. In this regard, analyses of the Regenstrief Medical Record System found a lower incidence of NMSC among individuals with diabetes who use insulin compared to those who do not use insulin [Standardized Incidence Ratio (SIR) .53; 95% CI: .31-.84]. 30 However, confounding factors such as smoking, level of education, income level, or employment status were not accounted for in these analyses. 30

Social determinants of health (SDOH) are a cluster of factors that are known to have a significant impact on the health and well-being of individuals. These factors include socioeconomic status, education, employment, access to healthcare, and other environmental factors. Studies have shown that SDOH contribute to the prevalence of non-communicable diseases (NCDs), including NMSC.31-33 One example of how SDOH can affect NMSC prevalence is through racial disparities in skin cancer rates. In the United States (US), skin cancer is more prevalent among White individuals, with 20%-30% of all cases occurring among this demographic. By contrast, skin cancer rates are significantly lower among Asians (2%-4%) and Black individuals (1%-2%). 34 Furthermore, education has been identified as a significant predictor of skin cancer knowledge and awareness. Individuals with higher levels of education are more likely to be aware of the risks associated with exposure to UV radiation and may take precautionary steps to protect themselves from the sun. On the other hand, people with lower levels of education may not be aware of the risks or may have limited access to preventive measures, such as sunscreen or protective clothing. 35

Consequently, the extent to which insulin use influences the risk of NMSC in light of SDOH is yet to be determined. To address this gap in knowledge, we conducted a quantitative study that comprehensively examined the interplay between insulin use, SDOH, and additional covariates (including age, sex, BMI, smoking, and heavy alcohol consumption) on the occurrence of NMSC. Our study focused on a population of individuals with diabetes who participated in the 2020 Behavioral Risk Factor Surveillance System (BRFSS).

Methods

Study Population and Sampling

Our study population was based on the BRFSS conducted by the Centers for Disease Control and Prevention (CDC) in the year 2020 which includes information on US residents concerning their health-related risk behaviors, chronic health conditions, and use of preventative services. Data was collected through self-reported surveys from adult participants (aged 18 or above) from all over the US. 36

The BRFSS followed a multistage cluster design in which each participant is chosen randomly for the interview. Question about whether or not the participant had any skin cancer was asked in the “Chronic Health Condition” module that was administered in all 50 states. However, the question about the most recent type of cancer, through which those with skin cancer distinguished between whether the skin cancer was NMSC or other type of skin cancer was asked in a different module which is the “Cancer Survivorship”. In addition, the age of diagnosis with the first cancer type was also asked in this module. As for diabetes, age of diagnosis with diabetes, was included as a question in the “Chronic Health conditions” module, whereas inslin use was included in the “Diabetes” module. The Cancer Survivorship and Diabetes modules were not administered in all 50 states, as a result, we only included respondents from the following 8 states that administered the modules that had questions on type of most recent cancer, age of diagnosis with the first type of cancer, age of diagnosis with diabetes, and insulin use. These included the states of Delaware, Georgia, Indiana, Mississippi, Missouri, South Dakota, Virginia, and Wisconsin. Participants were excluded if they reported having no diabetes, pre-diabetes or borderline diabetes, gestational diabetes, or had missing data on their diabetes status. Accordingly, a total sample of 8685 participants with diabetes was considered in this study (Figure 1).

Figure 1.

Figure 1.

Flowchart depicting how the final sample size was reached.

Concepts and Measures

The dependent variable used in our logistic regression was NMSC dichotomized into having this disease or not, while the outcome employed in our survival analysis was time to develop NMSC. The NMSC was determined by the question on type of most recently diagnosed cancer, included in the Cancer Survivorship module administered in some of the states as was indicated earlier. The time point of when the participant developed NMSC was determined by age of diagnosis of NMSC which is self-reported. Similarly, diabetes was assessed by the question on whether or not the participant was diagnosed with this disease. The time point when the participant developed diabetes was determined by age of diagnosis with diabetes which is also self-reported. The time-to-event which is time-to-NMSC was determined as the time period that elapsed from the age participant was diagnosed with diabetes till the age of developing NMSC. So the time-to-event reflects the difference in years between the age of diagnosis with NMSC and age of diagnosis with diabetes. However, it is important to note that for participants with more than 1 cancer type, the age of diagnosis with cancer was reported for the first type of cancer, which could be NMSC or other types of cancer. Thereofore, to take this point into consideration we carried out additional survival analysis whereby we included participants who either had only one type of cancer, or did not have NMSC. This sub-analysis ensured that for participants who had NMSC as the only type of cancer, the age of diagnosis was purely pertinent to NMSC, and time-to-event was the elapsed period from the age of diagnosis with diabetes till the age of diagnosis with NMSC.

The independent variables were insulin use and SDOH that included homeownership, marital status, healthcare coverage, employment status, urban/rural county, education level, income level, and race. The insulin use was assessed through a question asking the diabetic participants to self-report if they are currently using insulin or not. We also considered other covariates as potential associated factors with NMSC which included age, sex, body-mass index (BMI), smoking status, and heavy alcohol consumption. Insulin use, SDOH and the other covariates are all self-reported as time stationary variables and not time varying, and reflect the current time when the survey was filled in. The classifications of the different levels of the variables were detailed in Table 1.

Table 1.

Characteristics of the Study Sample.

Variables N a Weighted %
NMSC b
 Yes 487 4.8
 No 8110 95.2
Insulin use
 Yes 2803 33
 No 5637 67
Among those with NMSC
 Insulin use yes 130 22.2
 Insulin use No 357 77.8
Social determinants of health
 Home ownership
  Own 6402 77.2
  Rent 1864 19.7
  Other Arrangement 353 3.1
 Marital status
  Married or coupled 4295 56.6
  Divorced or separated 1689 18.3
  Widowed 1689 13.8
  Never married 962 11.3
 Health care coverage
  Yes 8189 92.8
  No 455 7.2
 Employment status
  Employed or self-employed 2398 34
  Out of work/Unable to work 1685 21.6
  Homemaker/Student 309 4.6
  Retired 4177 39.8
 Urban/Rural county
  Urban 6925 85.5
  Rural 1760 14.5
 Education level
  Graduated high school 2794 31.8
  Did not graduate high school 979 16.5
  Attended college or technical school 2499 31.5
  Graduated college or technical school 2373 20.2
 Income level
  Less than $15,000 980 14
  $15,000 to less than $25,000 1547 21.7
  $25,000 to less than $35,000 870 11.7
  $35,000 to less than $50,000 1014 14.1
  More than $50,000 2479 38.5
 Race
  White only 5998 69.1
  Black or African American only 1856 23.9
  Asian only 59 2.2
  Other race only c 464 3.2
  Multiracial 164 1.6
Other covariates
 Age
  18 to 44 597 12.3
  45 to 54 985 14.8
  55 to 64 2076 27.4
  65 or older 4895 45.5
 Sex
  Male 3923 49.3
  Female 4762 50.7
 Body-Mass index (BMI) d
  Normal weight 1034 13.6
  Underweight 56 0.7
  Overweight 2442 29.8
  Obese 4369 55.9
 Smoking status
  Never smoked 4320 51.3
  Current smoker 1125 15.3
  Former smoker 2868 33.4
 Alcohol consumption e
  Not a heavy drinker 7988 96.9
  Heavy drinker 209 3.1

aUnweighted counts.

bNon-Melanoma Skin Cancer.

cOther race included American Indian, Alaskan Native, Native Hawaiian/other Pacific Islander, or those who did not identify with any of the aforementioned race categories.

dAccording to the Centers for Disease Control and Prevention (CDC) classification, BMI was classified into 4 categories: underweight (less than 18.5 kg/m2), normal weight (between 18.5 kg/m2 and 25.0 kg/m2), overweight (between 25.0 kg/m2 and 30.0 kg/m2), or obese (more than 30.0 kg/m2).

eHeavy drinkers are defined in the Behavioral Risk Factor Surveillance System (BRFSS) as a man who consumes more than 14 drinks per week or a woman who consumes more than 7 drinks per week.

Statistical Analysis

To account for the BRFSS survey’s complex sampling design, we conducted weighted analyses using sampling and cluster weights. Frequency analyses were conducted, and respective summary statistics including counts and weighted percentages were reported for all the variables. Descriptive analysis along with weighted chi-squared tests and weighted simple logistic regressions were performed to determine the distribution of insulin use, the main exposure in this study, among the levels of each variable, and the extent of its correlation with the social and other factors considered in our analysis. Counts, weighted percentages, unadjusted odds ratios (ORs), 95% confidence intervals (CIs), and P-values were reported. Following that, frequency analysis showing the distribution of NMSC among the levels of each variable was conducted, in addition to performing the crude analysis using weighted simple logistic regression to assess the relationship between insulin use, SDOH, the other covariates, and NMSC (outcome of interest). Counts and weighted percentages for NMSC were generated, and unadjusted ORs and 95% CIs were calculated. The cutoff for eligibility for multiple logistic regression was raised to .2, as the significance level of .05 has been shown to fail in effectively selecting covariates associated with the outcome.37,38 Therefore, variables with P-values of .2 or less were considered eligible to be included in the adjusted analyses. Weighted multiple logistic regression was carried out to generate adjusted measures of association between insulin use, SDOH, and the other covariates as predictors and NMSC as the outcome.

Survival analysis was also conducted to assess the effect of insulin use on the time-to-develop NMSC. For uncensored participants who developed NMSC, the time-to-event endpoint was taken as the time from the diagnosis of diabetes to the time of diagnosis with NMSC. Participants who did not develop NMSC at the time of the study were considered censored, and censoring time was defined as the duration of diabetes that passed without experiencing the event of NMSC. To test if the proportional-hazards assumption was met in all our survival analysis models, we conducted a test of proportionality of hazards that is based on Schoenfeld residuals. A P-value for the global test of porportinality of hazards that is greater than .05 indicated that this assumption was met.

Kaplan-Meier survival analysis and log-rank test were performed to compare the probability of survival with NMSC event-free among participants who use and do not use insulin, and were also carried out for indices of SDOH that were shown to be significantly associated with time-to-NMSC in the multivariable survival model. The time-to-event depicted in the Kaplan Meier curve was in years which represents the difference between age of diagnosis in NMSC and diabetes. Specifically, it respresents the time period that elapsed between diagnosis with diabetes till diagnosis with NMSC. The stratification into insulin use or not is done based on whether or not currently the participant is taking insulin, but it cannot be determined from the data when exactly the participant started taking insulin. Participants who survive long enough to take insulin are those who are classified as insulin-users. However, those who die before they have the chance to take insulin are considered non-insulin users, but this group of participants did not participate in the study since information is self-reported by the participants themselves. Data on duration of insulin use is not collected in the BRFSS data so analysis cannot be adjusted for the effect of duration of insulin intake.

Weighted unadjusted and adjusted survival analyses using Cox proportional hazards were conducted to model the time-to-NMSC as a function of insulin use, SDOH, and the other covariates. Unadjusted and adjusted hazard ratios (HR) and their corresponding 95% CIs were generated and reported in our results.

Results

Characteristics of the Study Sample

The characteristics of the participants included in this study are displayed in Table 1. Summary statistics are presented in terms of frequency (N) and weighted percentages to account for the sampling design. Out of the 8685 participants, 4.8% (n = 487) had NMSC, and 33% (n = 2803) were using insulin therapy. More specifically, among participants who have NMSC (n = 487), 22.2% were using insulin therapy (n = 130), while the remaining majority (77.8%, n = 357) were not using insulin. Majority of the participants owned their home (77.2%, n = 6402), were married or coupled (56.6%, n = 4295), had healthcare coverage (92.8%, n = 8189), and lived in an urban county (85.5%, n = 6925). Moreover, 39.8% (n = 4177) were retired and 34% (n = 2398) were employed or self-employed. With respect to educational level, around 31% graduated high school (n = 2794) or attended college or technical school (n = 2499). The biggest proportion of the participants had an income of more than $50,000 (38.5%, n = 2479), and reported their race as White (69.1%, n = 5998). Almost half of the participants were females (50.7%, n = 4762), and had an age of 65 years or above (45.5%, n = 4895). More than half of the participants were obese (55.9%, n = 4369), never smoked (51.3%, n = 4320), and most of them were not heavy drinkers (96.9%, n = 7988).

Frequency Distibution of the SDOH and the Other Covariates in the Insulin Use and NMSC

The frequency distribution of the SDOH and the other covariates among insulin users and non-users, and among participants with and without NMSC are presented in terms of weighted column percent in Table 2, as well as Tables 3 and Supplemental Table A1 respectively.

Table 2.

Frequency Distribution of Insulin Use in Each Category of the Different Variables, and Frequency Distribution of Each Category of the Variables Between Insulin Users and Non Users Along With the Association Between Social Determinants of Health, Other Covariates, and Insulin Use (Outcome).

Variables Insulin Use N (Weighted Row %) a [Weighted Column %] b No Insulin Use N (Weighted Row %) c [Weighted Column %] d p-value e Weighted Unadjusted OR (95%CI) f P-value f
Social determinants of health
 Home ownership
  Own 1938 (31.7) [74.9] 4310 (68.3) [79.3] .005* Ref
  Rent 726 (37.8) [21.9] 1063 (62.2) [17.7] 1.31 (1.10-1.56) .002*
  Other Arrangement 116 (34.1) [3.2] 222 (65.9) [3.0] 1.11 (.79-1.56) .54
 Marital status
  Married or coupled 1294 (31.8) [54.8] 2871 (68.2) [57.9] .14 Ref
  Divorced or separated 592 (34.5) [18.9] 1051 (65.5) [17.6] 1.13 (.93-1.38) .20
  Widowed 547 (32.4) [13.7] 1106 (67.6) [14.0] 1.03 (.85-1.25) .77
  Never married 352 (37.3) [12.5] 577 (62.7) [10.3] 1.28 (1.01-1.61) .04*
 Health care coverage
  No 147 (37.1) [8.1] 293 (62.9) [6.8] .24 Ref
  Yes 2644 (32.6) [[91.9] 5316 (67.4) [93.2] .82 (.58-1.15) .24
 Employment status
  Employed or self-employed 635 (28.8) [29.7] 1676 (71.2) [36.2] <.001* Ref
  Out of work/Unable to work 722 (42.4) [27.4] 912 (57.6) [18.4] 1.82 (1.47-2.24) <.001*
  Homemaker/Student 84 (28.0) [3.8] 218 (72.0) [4.9] .96 (.64-1.44) .85
  Retired 1331 (32.3) [39.1] 2750 (67.7) [40.5] 1.18 (.99-1.41) .07
 Urban/Rural county
  Urban 2160 (32.6) [84.5] 4555 (67.4) [85.8] .24 Ref
  Rural 643 (35.0) [15.5] 1082 (65.0) [14.2] 1.11 (.93-1.32) .24
 Education level
  Graduated high school 940 (33.9) [33.0] 1796 (66.1) [31.7] .03* Ref
  Did not graduate high school 366 (37.4) [19.1] 594 (62.6) [15.7] 1.17 (.93-1.46) .18
  Attended college or technical school 805 (31.7) [30.2] 1628 (68.3) [31.9] .91 (.76-1.09) .30
  Graduated college or technical school 678 (29.7) [17.7] 1595 (70.3) [20.7] .82 (.68-.98) .05*
 Income level
  Less than $15,000 377 (38.9) [16.3] 572 (61.1) [12.6] <.001* Ref
  $15,000 to less than $25,000 583 (37.8) [25.0] 939 (62.2) [20.3] .95 (.73-1.24) .71
  $25,000 to less than $35,000 289 (34.4) [12.2] 561 (65.6) [11.5] .82 (.60-1.12) .21
  $35,000 to less than $50,000 298 (28.6) [12.2] 690 (71.4) [15.1] .63 (.46-.85) .002*
  More than $50,000 666 (29.5) [34.3] 1716 (70.5) [40.5] .66 (.51-.84) .001*
 Race
  White only 1847 (31.4) [66.4] 3982 (68.6) [71.0] .12 Ref
  Black or African American only 642 (36.7) [26.6] 1171 (63.3) [22.4] 1.26 (1.06-1.51) .01*
  Asian only 12 (26.6) [1.7] 42 (73.4) [2.4] .79 (.33-1.88) .59
  Other race only 213 (41.4) [3.9] 237 (58.6) [2.7] 1.54 (1.01-2.35) .05*
  Multiracial 45 (30.3) [1.4] 112 (69.7) [1.5] .95 (.44-2.05) .89
Other covariates
 Age
  18 to 44 215 (37.5) [13.8] 349 (62.5) [11.3] .21 Ref
  45 to 54 321 (33.9) [15.0] 623 (66.1) [14.3] .85 (.62-1.17) .33
  55 to 64 707 (32.6) [27.2] 1314 (67.4) [27.7] .80 (.61-1.07) .13
  65 or older 1526 (31.7) [44.0] 3258 (68.3) [46.7] .77 (.59-.98) .05*
 Sex
  Male 1251 (32.6) [49.0] 2552 (67.4) [49.6] .66 Ref
  Female 1552 (33.3) [51.0] 3085 (66.7) [50.4] 1.03 (.89-1.19) .66
 Body-Mass index (BMI)
  Normal weight 310 (33.7) [13.8] 699 (66.3) [13.5] .49 Ref
  Underweight 21 (39.5) [.8] 34 (60.5) [.6] 1.28 (.57-2.90) .55
  Overweight 729 (31.4) [28.1] 1645 (68.6) [30.6] .90 (.69-1.17) .44
  Obese 1510 (34.1) [57.3] 2735 (65.9) [55.3] 1.02 (.79-1.30) .89
 Smoking status
  Never smoked 1344 (31.9) [49.5] 2860 (68.1) [52.3] .30 Ref
  Current smoker 378 (33.6) [15.4] 710 (66.4) [15.1] 1.08 (.87-1.34) .50
  Former smoker 962 (34.8) [35.1] 1827 (65.2) [32.6] 1.14 (.97-1.33) .12
 Alcohol consumption
  Not a heavy drinker 2605 (33.5) [97.6] 5156 (66.5) [96.5] .15 Ref
  Heavy drinker 48 (25.5) [2.4] 155 (74.5) [3.5] .68 (.40-1.16) .15

aFrequency distribution (unweighted counts and weighted percentages) of insulin use in each category of the variables.

bWeighted percentages of each category of the variables among insulin users.

cFrequency distribution (unweighted counts and weighted percentages) of no insulin use in each category of the variables.

dWeighted percentages of each category of the variables among non-insulin users.

eWeighted Chi-square test showing the unadjusted association between each variable and insulin use.

fWeighted simple logistic regression showing the unadjusted associations between each level of the variable in comparison with the reference category and insulin use.

*P-value < .05 indicating significant results.

Table 3.

Frequency Distribution of NMSC in Each Category of the Different Variables, and Frequency Distribution of Each Category of the Variables for Participants With and Without NMSC, Along With the Unadjusted and Adjusted Associations Between Insulin Use, Social Determinants of Health, Other Covariates, and NMSC a (Outcome).

NMSC a NMSC (Weighted Row %) b [Weighted Column %] c No NMSC (Weighted Row %) d [Weighted Column %] e Weighted Unadjusted OR (95%CI) f Weighted Adjusted OR (95%CI) g P-Value g
Insulin use
 No 357 (5.8) [77.8] 5226 (94.2) [66.5] Ref Ref
 Yes 130 (3.4) [22.2] 2640 (96.6) [33.5] .57 (.41-.77) .56 (.38-.82) .003*
Social determinants of health
 Home ownership
  Own 425 (5.6) [90.6] 5904 (94.4) [76.4] Ref Ref
  Rent 46 (1.9) [7.9] 1806 (98.1) [20.4] .33 (.21-.51) .75 (.41-1.40) .37
  Other Arrangement 12 (2.2) [1.5] 339 (97.8) [3.2] .38 (.14-1.07) .64 (.15-2.64) .53
 Marital status
  Married or coupled 290 (5.9) [69.2] 3956 (94.1) [56.0] Ref Ref
  Divorced or separated 54 (2.8) [10.5] 1623 (97.2) [18.6] .45 (.28-.73) .74 (.42-1.32) .31
  Widowed 117 (5.8) [16.4] 1548 (94.2) [13.5] .98 (.69-1.40) .98 (.65-1.49) .94
  Never married 23 (1.6) [3.9] 936 (98.4) [11.8] .27 (.14-.50) .74 (.36-1.55) .43
 Employment status
  Employed or self-employed 84 (2.7) [18.7] 2300 (97.3) [34.9] Ref Ref
  Out of work/Unable to work 45 (3.9) [17.5] 1631 (96.1) [21.8] 1.49 (.80-2.75) 3.40 (1.47-7.86) .004*
  Homemaker/Student 15 (5.2) [4.9] 287 (94.8) [4.6] 2.00 (.64-6.27) 2.39 (.70-8.15) .16
  Retired 339 (7.2) [58.9] 3781 (92.8) [38.7] 2.84 (2.05-3.93) 1.88 (1.20-2.93) .01*
  Education level graduated high school 122 (4.0) [26.5] 2639 (96.0) [32.0] Ref Ref
  Did not graduate high school 29 (2.9) [10.0] 936 (97.1) [16.8] .73 (.42-1.27) 1.01 (.51-1.99) .98
  Attended college or technical school 161 (6.2) [40.9] 2313 (93.8) [31.1] 1.59 (1.08-2.36) 1.62 (1.04-2.51) .03*
  Graduated college or technical school 173 (5.4) [22.6] 2184 (94.6) [20.1] 1.36 (.97-1.92) 1.30 (.86-1.97) .21
 Income level
  Less than $15,000 30 (2.4) [6.9] 944 (97.6) [14.4] Ref Ref
  $15,000 to less than $25,000 52 (2.8) [12.1] 1472 (97.2) [22.0] 1.16 (.62-2.17) .91 (.45-1.83) .79
  $25,000 to less than $35,000 47 (4.9) [11.5] 812 (95.1) [11.8] 2.05 (1.04-4.01) 1.38 (.65-2.95) .40
  $35,000 to less than $50,000 70 (6.5) [18.3] 938 (93.5) [13.8] 2.77 (1.27-6.01) 1.80 (.71-4.62) .22
  More than $50,000 192 (6.6) [51.2] 2269 (93.4) [38.0] 2.82 (1.63-4.88) 2.10 (1.02-4.33) .04*
 Race
  White only 460 (6.9) [97.0] 5458 (93.1) [68.0] Ref Ref
  Black or African American only 4 (.2) [.8] 1848 (99.8) [26.0] .02 (.01-.06) .03 (.01-.11) <.001*
  Other race only 8 (2.4) [1.6] 453 (97.6) [4.0] .33 (.15-.76) .55 (.21-1.44) .22
  Multiracial 9 (1.7) [.6] 155 (98.3) [2.0] .23 (.09-.57) .28 (.09-.90) .03*
Other covariates
 Age
  18 to 44 5 (.6) [1.6] 591 (99.4) [13.0] Ref Ref
  45 to 54 12 (2.1) [6.5] 966 (97.9) [15.3] 3.35 (.71-15.78) 2.17 (.52-8.99) .28
  55 to 64 76 (4.2) [23.9] 1986 (95.8) [27.6] 6.88 (2.34-20.22) 3.43 (1.08-10.94) .04*
  65 or older 387 (7.3) [68.0] 4444 (92.7) [44.1] 12.24 (4.40-34.04) 5.71 (1.90-17.11) .002*
 Smoking status
  Never smoked 264 (5.4) [55.3] 4011 (94.6) [51.1] Ref Ref
  Current smoker 35 (1.9) [5.9] 1080 (98.1) [15.8] .34 (.20-.58) .50 (.28-.90) .02*
  Former smoker 186 (5.9) [38.8] 2650 (94.1) [33.1] 1.08 (.79-1.49) .94 (.67-1.32) .71

aNon-Melanoma Skin Cancer.

bFrequency Distribution (unweighted counts and weighted percentages) of NMSC in each category of the variables.

c Weighted percentagesof each category of the variables for participants with NMSC.

dFrequency Distribution (unweighted counts and weighted percentages) of no NMSC in each category of the variables.

eWeighted percentages of each category of the variables for particpants without NMSC.

fWeighted simple logistic regression showing the unadjusted associations between each level of the variable in comparison with the reference category and NMSC.

gWeighted multiple logistic regression showing the adjusted associations between each level of the variable in comparison with the reference category and NMSC.

*P-value < .05 indicating significant results.

Our results showed that for the variables that had significant association with insulin, the highest percentages of insulin use were among homeowners (74.9%), married or coupled (54.8%), retired (39.1%), graduated high school (33%), had an income that is more than $50,000 (34.3%), white race (66.4%), and age 65 or older (44%) (Table 2).

As for the frequency distribution of the SDOH and other covariates among participants with NMSC which had significant adjusted association with NMSC, our results showed that 22.2% of NMSC participants were using insulin, 58.9% were retired, 40.9% attended college or technical school, 51.2% had an income of more than $50,000, 97% were of white race, 68% had an age of 65 years or older, and 5.9% were current smokers (Table 3).

Frequency Distribution of Insulin Use in Each Category of the Different Variables and its Association with SDOH and Other Covariates

The frequency distribution of insulin use among the SDOH and the other covariates expressed in terms of weighted row percentages, along with the weighted unadjusted ORs and the 95% CIs are presented in Table 2. Our sub-analysis indicated that there is a significant association between insulin use and the different indices of SDOH that included categories of home ownership, marital status, employment status, education level, income level, race, and age.

In this regard, our results showed that there was an increase in the weighted odds and percentages of insulin use among participants who rented their home (OR 1.31; 95% CI: 1.10-1.56; 37.8%), have never been married (OR 1.28; 95% CI: 1.01-1.61; 37.3%), are out of work/unable to work (OR 1.82; 95% CI: 1.47-2.24; 42.4%), and who are Black (OR 1.26; 95% CI: 1.06-1.51; 36.7%), or of other race (OR 1.54; 95% CI: 1.01-2.35; 41.4%) compared to their respective reference categories shown in Table 2. On the other hand, our results also indicated that there was a decrease in the odds and percentages of insulin use among participants who reported their level of education as graduated college or technical school (OR .82; 95% CI: .68-.98; 29.7%), have an income between $35,000 and $50,000 (OR .63; 95% CI: .46-.85; 28.6%), or more than $50,000 (OR .66; 95% CI: .51-.84; 29.5%), and are of older age of 65 years and more (OR .77; 95% CI 0.59-.99; 31.7%), in comparison with their respective reference groups presented in Table 2.

Frequency Distribution of NMSC in Each Category of the Different Variables and its Association with Insulin Use, Social Determinants of Health, and Other Covariates

Supplemental Table A1 and Table 3 display the frequency distribution of NMSC in each category of the different variables, along with the unadjusted and adjusted associations expressed in terms of the weighted ORs, 95% CI, and P-values between insulin use, SDOH, the other covariates, and NMSC (outcome) respectively.

Our adjusted weighted logistic regression analysis showed that participants using insulin, who are Black, multiracial, and currently smoking had lower weighted percentages of NMSC and decreased weighted odds of NMSC compared to their respective reference categories (Table 3). In this respect, our results indicated that 3.4% of participants using insulin had NMSC, while 5.8% of participants who do not use insulin had NMSC; in addition, insulin use was significantly associated with decreased odds of NMSC by .56 (reflecting a reduction of 43% in the odds) compared to no insulin use (95%CI: .38-.82). Our results also showed that NMSC was less prevalent among Black individuals (.2%) and multiracial individuals (1.7%) who also had decreased odds of NMSC of .03 (95% CI: .01-.11), and .28 (95% CI: .09-.9), respectively, when compared to White individuals (6.9%). Moreover, our results also indicated that current smokers had lower weighted percentages of NMSC (1.9%), and reduced odds of NMSC of .50 (95% CI: .28-.90) compared to participants who never smoked (5.4%).

On the other hand, NMSC was more prevalent among participants who were out of work/unable to work (3.9%), retired (7.2%), attended college/technical school (6.2%), had income of more than $50,000 (6.6%), and were aged between 55 and 64 years (4.2%), or more than 65 years (7.3%) compared to their respective reference levels shown in Table 3. These categories were also associated with increased odds of NMSC, with out of work/unable to work having an OR of 3.40 (95% CI: 1.47-7.86), retired (OR 1.88; 95% CI: 1.20-2.93), attended college or technical school (OR 1.62; 95% CI: 1.04-2.51), an income of more than $50,000 (OR 2.10; 95% CI: 1.02-4.33), age between 55 and 64 years (OR 3.43; 95% CI: 1.08-10.94), and more than 65 years (OR 5.71; 95% CI: 1.90-17.11).

Association Between Insulin Use, Social Determinants of Health, Other Covariates, and the Time-To-NMSC

Figure 2 displays the Kaplan-Meier survival estimates for the time-to-diagnosis with NMSC pertaining to participants who use insulin compared to those who do not use insulin. The probability of event-free survival was significantly higher for participants who use insulin compared to those who do not use insulin (P < .001 by the log-rank test). Supplemental Table A2 and Table 4 respectively display the results of the simple and multiple Cox proportional hazards analysis with outcome time-to-NMSC expressed as a function of insulin use, SDOH, and other variables. The unadjusted and adjusted weighted hazard ratios (HRs) for NMSC were presented in Supplemental Table A2 and Table 4 respectively. The assumption of proportionality of hazard was tested for and confirmed for the survival multivariable model presented in Table 4 with a global P = .48.

Figure 2.

Figure 2.

Kaplan-Meier survival curves and Log Rank test for time-to-diagnosis with NMSC among participants who use insulin compared to those who do not use insulin.

Table 4.

Unadjusted and Adjusted Hazard Ratios (HR) for Time-To-NMSC. a

Variables Weighted Unadjusted HR (95% CI) b Weighted Adjusted HR (95% CI) c P-Value c
Insulin use
 No Ref Ref
 Yes .40 (.26-.62) .36 (.21-.62) <.001*
Social determinants of health
 Home ownership
  Own Ref Ref
  Rent .38 (.19-.75) .71 (.30-1.68) .43
  Other Arrangement .62 (.16-2.41) 1.15 (.21-6.33) .87
 Marital status
  Married or coupled Ref Ref
  Divorced or separated .54 (.26-1.10) .80 (.35-1.79) .58
  Widowed .81 (.50-1.31) 1.05 (.58-1.89) .87
  Never married .27 (.12-.64) .48 (.17-1.38) .17
 Employment status
  Employed or self-employed Ref Ref
  Out of work/Unable to work 1.22 (.47-3.14) 3.94 (1.18-13.23) .03*
  Homemaker/Student .81 (.30-2.19) 1.21 (.38-3.82) .75
  Retired 1.65 (1.05-2.60) 1.90 (1.11-3.24) .02*
 Education level
  Graduated high school Ref Ref
  Did not graduate high school .57 (.27-1.22) .75 (.32-1.74) .50
  Attended college or technical school 2.07 (1.21-3.54) 1.88 (1.05-3.36) .03*
  Graduated college or technical school 1.60 (.99-2.60) 1.42 (.82-2.46) .21
 Income level
  Less than $15,000 Ref Ref
  $15,000 to less than $25,000 .70 (.30-1.66) .62 (.25-1.55) .31
  $25,000 to less than $35,000 1.65 (.66-4.13) 1.21 (.47-3.14) .69
  $35,000 to less than $50,000 3.08 (.99-9.56) 2.18 (.55-8.64) .27
  More than $50,000 2.57 (1.19-5.51) 2.01 (.78-5.17) .15
 Race
  White only Ref Ref
  Black or African American only .02 (.005-.09) .03 (.01-.13) <.001*
  Other race only .29 (.003-.21) .05 (.01-.39) .004*
  Multiracial .20 (.06-.74) .27 (.07-1.05) .06
Other covariates
 Smoking status
  Never smoked Ref Ref
  Current smoker .36 (.16-.83) .48 (.20-1.13) .09
  Former smoker 1.03 (.66-1.62) .90 (.55-1.45) .66

aNon-Melanoma Skin Cancer.

bWeighted simple survival analysis using Cox proportional hazards showing the unadjusted associations between each level of the variable in comparison with the reference category and Time-to-NMSC.

cWeighted multiple survival analysis using Cox proportional hazards showing the adjusted associations between each level of the variable in comparison with the reference category and Time-to-NMSC.

P-value < .05 indicating significant results.

In the adjusted survival analysis (Table 4), a significant association was detected between insulin use and NMSC indicating that participants with diabetes who use insulin had a 64% reduction in the hazard of developing NMSC (HR .36; 95% CI: .21-.62) compared to participants with diabetes who do not use insulin. Furthermore, our analysis of SDOH indicated that participants who are out of work/unable to work, or retired had higher hazard of 3.94 (95% CI: 1.18-13.23) and 1.90 (95% CI: 1.11-3.24) respectively to develop NMSC, compared to participants who are employed or self-employed. Kaplan-Meier survival curves shown in Figure 3(a) also showed a significant association between employment status and time-to-NMSC with log-rank test P < .001, with a lower survival curve pertinent to retired compared to employed or self-employed.

Figure 3.

Figure 3.

Kaplan-Meier survival curves (a-c), and Log-Rank tests for selected indices of Social Determinants of Health and time-to-NMSC.

In addition, study participants who attended college or technical school had a higher hazard of NMSC of 1.88 (95% CI: 1.05-3.36) compared to participants who only graduated high school, and lower survival curve as illustrated in Figure 3(b) (log-rank test P < .001).

With respect to race, Black/African American participants (HR .03; 95% CI: .01-.13) and participants who reported being from other races (HR .05; 95% CI: .01-.39) had significantly lower hazards of developing NMSC compared to White participants, and higher survival curves as shown in Figure 3(c) (log-rank test P < .001).

To address the issue of multiple cancers, we carried out additional multivariable sub-group analysis using the multiple Cox proportional hazards with outcome time-to-NMSC on participants who either had 1 type of cancer, or did not have NMSC (controls), excluding those with more than 1 type of cancer. A total of 117 participants with NMSC and multiple types of cancer were excluded from this sub-analysis out of a total of 487 NMSC cases, leaving a total of 370 participants with NMSC. This sub-analysis ensured that for the 370 participants who had NMSC, the age of diagnosis was purely pertinent to NMSC. Results of this sub-analysis, not presented in a table but discussed here, were in concordance with the aforementioned survival analysis that had all 487 NMSC cases included. Once more, insulin use for diabetic participants was shown to be associated with decreased hazard for NMSC with HR = .32; 95% CI: .17-.58; P < .001, (68% reduction in hazard). In addition, some indices of SDOH also showed significant associations with time-to-NMSC. These included, employment status comparing out of work/unable to Work to employed or self-employed (HR = 3.82; 95% CI: 1.10-13.24; P = .03); education level comparing attended college or technical school to graduated high school (HR = 1.89; 95% CI: 1.01-3.55; P = .04); and race comparing Black or African American (HR = .03 95% CI HR = .01-.14 P < .001); Other race (HR = .05 95% CI HR = .01-.41 P = .005); and Multiracial (HR = .16 95% CI HR = .03-.89 P = .03) to White. The propotional-hazards assumption for this sub-analysis was also assessed and confirmed with a global P = .61.

Discussion

Our study underscored the complex relationship between insulin use and NMSC by demonstrating that socioeconomic disparities are related to differences in insulin use and the development of NMSC. Our findings emphasize the importance of considering various factors, including insulin use and SDOH, in the prevention and management of NMSC among individuals with diabetes.

In this regard, our results showed that individuals with diabetes using insulin had 44% lower odds of developing NMSC compared to those who do not use insulin therapy. Furthermore, Kaplan-Meier survival curves showed that the likelihood of being NMSC-free was higher for participants with diabetes who were using insulin compared to those who were not. In addition, our Cox-proportional weighted analysis revealed a 64% lower hazard of developing NMSC among participants who use insulin. In line with our findings, insulin therapy in diabetic patients was shown to lower the risk of developing NMSC and the protective effect of insulin use becomes more distinct with increasing age. 30 Moreover, insulin use improved the 5-year progression-free survival in diabetic patients with coexisting melanoma. 39 The underlying molecular and mechanistic pathways through which insulin therapy reduces the risk to develop NMSC in individuals with diabetes are still not clearly defined. It is conceivable that the link between insulin use and reduction in NMSC risk is not direct but rather multifactorial. Management of diabetes through insulin therapy will influence the metabolic state of the diabetic patients by controlling hyperglycemia, improving insulin resistance and attenuate the inflammatory and oxidative stress signals, factors that are associated with increased risk of developing NMSC in individuals with diabetes.40,41

Moreover, our analysis highlighted the association between the SDOH, other factors, and NMSC among individuals with diabetes. Socioeconomic status, access to medical care, culture and social setting, race, inequities in living and working environments have direct influence on biological and behavioral outcomes associated with insulin use and management of diabetes. 42 In this regard, our results showed that higher income levels and older age were significantly associated with a lower percentage of insulin use and increased odds of NMSC. On the other hand, Black participants showed a higher prevalence of insulin use and a decreased hazard of NMSC compared to White participants. The observed increased hazards of NMSC among unemployed and retired participants compared to employed or self-employed participants could be attributed to the difference in sun exposure, as those who do not have a job may spend more time outdoors during their free time, leading to increased exposure to UVB radiation in contrast to those who work during the day. 43 Moreover, retired individuals are typically older in age, which is another contributing factor to the higher prevalence of NMSC among this age group, as age is known to be a risk factor for cancer in general,30,44,45 including NMSC. 9

Our analyses also revealed that higher levels of education are associated with an increased hazard of developing NMSC. This discrepancy in NMSC risk among the different levels of education may be attributed to better access to health information and awareness of prevention strategies that people with higher education typically have. 46 Improved knowledge and awareness can lead to early recognition of signs and symptoms of NMSC and more frequent access to healthcare coverage and medical screening.46,47 Conversely, lower levels of education have been associated with decreased perceptions of the risks of skin cancer,48,49 lack of awareness of its early signs and symptoms, and missed opportunities for skin examinations. 37 These factors, combined, may explain the observed association between lower educational levels and advanced stages of skin cancer at diagnosis. 48 Moreover, the level of education influences the communication between healthcare professionals and patients about their health and diseases. In this respect, it was found that healthcare providers tend to share more detailed information on the risks of skin cancer and the importance of self-performed and medical skin examinations with patients who have a college education than with patients that have only a high school education. 48 Consequently, individuals with higher levels of education are more likely to have a better awareness of NMSC, and its diagnosis and prognosis.46,49

Our analysis further showed that individuals with higher income levels were associated with increased odds of NMSC. This result is in line with findings from the literature which reported that cases of skin cancer are more prevalent among people of higher socioeconomic status.46,50 Nevertheless, a high socioeconomic status does not necessarily imply a greater risk of NMSC; rather, it is more probable that it reflects an increased likelihood of detecting and reporting skin cancer. In fact, despite the higher reported prevalence of NMSC in populations with higher socioeconomic status, studies have shown that advanced stages of NMSC, thicker tumors, and a 5-year reduction in survival rates were more prevalent among underprivileged communities.46,50-52 These observations indicate that early recognition of signs and symptoms of skin cancer coupled with early diagnosis are less likely to be received for underprivileged individuals. A probable explanation for the aforementioned discrepancies in the detection of skin cancer can be referred to the inequity in accessing cancer screening and preventative healthcare facilities across the different socioeconomic classes. The privatized healthcare system in the US contributes to this disproportionality since thus far it has not succeeded in securing equitable healthcare coverage for all communities, 53 a drawback that needs to be accounted for when reforms are to be considered in the restructuring of the healthcare system.

Our study also revealed that White individuals were associated with a higher hazard of developing NMSC compared to the other races. This result is consistent with previously reported findings that underscored the disproportionate prevalence of skin cancer among different races in the US, with White individuals having the highest incidence rates. 34 Age-adjusted incidence rates in the US showed that White individuals are 70 times more likely to develop skin cancer compared to Black individuals, a discrepancy in skin cancer risk that may be attributed to biologic and genetic differences. 34 Nevertheless, despite having a lower risk of NMSC, Black individuals were found to present with a poorer prognosis and a higher mortality rate when diagnosed with this disease compared to White individuals.34,54 This racial disparity in survival outcomes may be related to the perception among Black individuals that they are less susceptible to skin cancer, 49 their likelihood of not seeking immediate medical consultancy for suspicious skin lesions or injury, 55 and subsequently their diagnosis with this disease at advanced stages 54 compared to White individuals.

It is important to point out here, that the prevalence and incidence of diabetes on risk and outcomes is vastly influenced by SDOH factors. People with lower socioeconomic status (SES) and lower educational levels are more likely to develop diabetes and are more susceptible to sub-optimal heath care management.42,56 In addition, disparities in racial and ethnic populations are associated with significantly higher prevalence and incidence of diabetes and access to quality care are more likely to experience greater levels of morbidity and early mortality.42,56 Financial hardship as well as psychosocial and neighborhood influences, such as social cohesion and religiosity, have been linked to poor glycemic control in older adults with diabetes resulting in adverse diabetes outcomes over time. 57 Accounting for these disparities in SDOH in the management of diabetes and to expand the utilization of technologies such as continuous glucose monitoring to underprivileged socioeconomic individuals will result in better glycemic control and ultimately lessen the adverse clinical outcomes of diabetes. 58

Strength and Limitations

The study is novel since it is the first to incorporate the social factors into the association with insulin use and NMSC, and triangulate these relationships. Moreover, basing our quantitative study on a large-scale surveillance system such as the CDC-BRFSS makes the generalizability of our inferences and results feasible since this data encompasses a national representation of the US population.

Despite the novelty in the research question and the strength in the selection of the BRFSS as our sample population, there are some limitations in this study. The BRFSS data is collected through telephone surveys and therefore the diagnosis of cancer and diabetes was self-reported. However, there is evidence that self-reported diagnoses are concordant enough with medical records. 59 Moreover, there is no distinction in our data between type I and type II diabetes. However, given that the age of diagnosis with type I diabetes is approximately below the age of 30 to 40 years and this forms only 8% to 24% of our sample, and given that the diagnosis with type II diabetes is typically above the age of 40 and this age group forms 76% to 92% of our data, then type II diabetes is expected to be much more prevalent in our sample. Nonetheless, given that there is no direct question on the type of diabetes, then this cannot be fully confirmed. Even though our study focused on diabetes mellitous (DM), selection bias should not be of concern since the frequency distributions of insulin use and SDOH, and their link to NMSC are considered among diabetic participants only. Accordingly, study population characteristics are compared between different variables within the sample of diabetic participants. The BRFSS data did not contain data on the concurrent medication the DM participant is taking other than insulin, accordingly the medication use such as statin, sulfonyl urea and drug-related to cancer incidence could not be adjusted for in the multivariable model. Morevoer, the BRFSS asked participants to report their most recent cancer type. Thus, participants with more than 1 type of cancer, could have had NMSC as an earlier type of cancer, but was not recorded since it is not the most recent type. This particular group of particiapnts are recorded as not having NMSC as their most recent cancer type, but could have had it in the past. In addition, participants with multiple types of cancer were asked to report only the age of diagnosis with their first type of cancer, not the age of diagnosis with their most recent cancer. To tackle this issue and to confirm our results, we carried out a sub-group analysis on participants who either reported having 1 type of cancer, or did not have NMSC cancer (controls). This sub-analysis ensured that for NMSC cases, the reported age of diagnosis was purely pertinent to NMSC and not for any other type of cancer. Results of this sub-analysis were in concordance with the survival model that encompassed all participants who did not have cancer, had 1 type of cancer or multiple cancers; whereby, similar conclusions were drawn in both survival analyses concerning the role of insulin use and SDOH on NMSC.

Conclusion

In conclusion, our study revealed a significant association between insulin use and reduced risk of NMSC among individuals with diabetes and underscored the critical role of SDOH in this relationship. Our findings suggest that insulin use may have a protective effect against NMSC and that indices of SDOH such as income, level of education, employment status, and race can significantly influence the likelihood of developing this disease, indicating potential disparities in exposure to risk factors and healthcare access across different socioeconomic groups. To ensure equal opportunities for skin cancer prevention, early detection, and improved prognosis, it is essential to address healthcare access inequities. Healthcare providers should consider several factors, including insulin use and SDOH when developing prevention and management strategies for NMSC in people with diabetes. While our results highlight the potential of insulin as a protective agent against NMSC, this knowledge can only have a meaningful impact on public health when it is accompanied by efforts to address health inequity in the early diagnosis of skin cancer and the associated treatment modalities, promote awareness of its risk factors, and advocate for access to healthcare across all social groups.

Supplemental Material

Supplemental Material - Role of Insulin Use and Social Determinants of Health on Non-melanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System

Supplemental Material for Role of Insulin Use and Social Determinants of Health on Non-melanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System by Nour Massouh, Ayad A. Jaffa, and Miran A. Jaffa in Cancer Control

Appendix.

List of Abbreviations

BMI

Body-Mass Index

BRFSS

Behavioral Risk Factor Surveillance System

CDC

Centers for Disease Control and Prevention

CI

Confidence Interval

DALYs

Disability-Adjusted Life Years

HR

Hazard Ratio

NCDs

Non-Communicable Diseases

NMSC

Non-Melanoma Skin Cancer

OR

Odds Ratio

SDOH

Social Determinants of Health

SGLT-2

Sodium-Glucose Co-Transporter-2

SIR

Standardized Incidence Ratio

US

United States

UV

Ultraviolet

UVB

Ultraviolet B

WHO

World Health Organization

Note

1.

CDC. 2020 BRFSS Survey Data and Documentation. 2021; https://www.cdc.gov/brfss/annual_data/annual_2020.html. Accessed April 11, 2022.

Authors’ Contributions: MAJ identified the BRFSS dataset. MAJ conceptualized the research ideas. MAJ and NM conceived the study concept and design. AAJ refined and finalized the conceptual research ideas. NM and MAJ carried out the data analysis. MAJ oversaw the data analysis. MAJ and AAJ supervised the impelementation of the project. NM drafted the manuscript. AAJ and MAJ extensively revised and edited the manuscript. NM, AAJ, and MAJ all approved the final version of the manuscript.

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

Supplemental Material: Supplemental material for this article is available online

Ethical Statement

Ethics Approval

Participants in the BRFSS provided informed consent and their privacy was protected as all information available for analysis by the CDC was de-identified. 1

Consent to Participate

Ethical review and approval were not required for this study.

ORCID iDs

Nour Massouh https://orcid.org/0000-0002-6865-4399

Miran A. Jaffa https://orcid.org/0000-0002-0318-7611

Data Availability Statement

The dataset supporting the conclusions of this article is available on the CDC website, https://www.cdc.gov/brfss/annual_data/annual_2020.html.

References

  • 1.Ciążyńska M, Kamińska-Winciorek G, Lange D, et al. The incidence and clinical analysis of non-melanoma skin cancer. Sci Rep. 2021;11(1):4337. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Faur CI, Moldovan MA, Văleanu M, Rotar H, Filip L, Roman RC. The prevalence and treatment costs of non-melanoma skin cancer in cluj-napoca maxillofacial center. 2023;59(2):220. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. [DOI] [PubMed] [Google Scholar]
  • 4.Eisemann N, Waldmann A, Geller AC, et al. Non-melanoma skin cancer incidence and impact of skin cancer screening on incidence. J Invest Dermatol. 2014;134(1):43-50. [DOI] [PubMed] [Google Scholar]
  • 5.NHS . Overview skin cancer (non-melanoma). 2020; https://www.nhs.uk/conditions/non-melanoma-skin-cancer/
  • 6.WHO . Radiation: ultraviolet (UV) radiation and skin cancer. 2017; https://www.who.int/news-room/questions-and-answers/item/radiation-ultraviolet-(uv)-radiation-and-skin-cancer
  • 7.Yazdi D, Jourabchi N. Skin cancer, non-melanoma. 2015:1064-1066. [Google Scholar]
  • 8.Gandhi SA, Kampp J. Skin cancer epidemiology, detection, and management. Med Clin North Am. 2015;99(6):1323-1335. [DOI] [PubMed] [Google Scholar]
  • 9.Urban K, Mehrmal S, Uppal P, Giesey RL, Delost GR. The global burden of skin cancer: a longitudinal analysis from the Global Burden of Disease Study, 1990-2017. JAAD Int. 2021;2:98-108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524-548. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dobrică EC, Banciu ML, Kipkorir V, et al. Diabetes and skin cancers: risk factors, molecular mechanisms and impact on prognosis. World J Clin Cases. 2022;10(31):11214-11225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Zhou D, Wu J, Luo G. Body mass index and risk of non-melanoma skin cancer: cumulative evidence from prospective studies. Sci Rep. 2016;6:37691. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Yen H, Dhana A, Okhovat JP, Qureshi A, Keum N, Cho E. Alcohol intake and risk of nonmelanoma skin cancer: a systematic review and dose-response meta-analysis. Br J Dermatol. 2017;177(3):696-707. [DOI] [PubMed] [Google Scholar]
  • 14.Alberg AJ, Shopland DR, Cummings KM. The 2014 surgeon general’s report: commemorating the 50th anniversary of the 1964 report of the advisory committee to the US surgeon general and updating the evidence on the health consequences of cigarette smoking. Am J Epidemiol. 2014;179(4):403-412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Yeh HC, Golozar A, Brancati FL. Cancer and diabetes. In: Cowie CC, Casagrande SS, Menke A, et al. , eds. Diabetes in America. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018. [PubMed] [Google Scholar]
  • 16.Arafa A, Mostafa A, Navarini AA, Dong J-Y. The association between smoking and risk of skin cancer: a meta-analysis of cohort studies. Cancer Causes Control. 2020;31(8):787-794. [DOI] [PubMed] [Google Scholar]
  • 17.Rollison DE, Iannacone MR, Messina JL, et al. Case-control study of smoking and non-melanoma skin cancer. Cancer Causes Control. 2012;23(2):245-254. [DOI] [PubMed] [Google Scholar]
  • 18.WHO . Diabetes. 2023. https://www.who.int/news-room/fact-sheets/detail/diabetes
  • 19.Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. Diabetes and cancer. Endocr Relat Cancer. 2009;16(4):1103-1123. [DOI] [PubMed] [Google Scholar]
  • 20.Tseng H-W, Shiue Y-L, Tsai K-W, Huang W-C, Tang P-L, Lam H-C. Risk of skin cancer in patients with diabetes mellitus: a nationwide retrospective cohort study in Taiwan. Medicine (Baltimore). 2016;95(26):e4070. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wotton CJ, Yeates DGR, Goldacre MJ. Cancer in patients admitted to hospital with diabetes mellitus aged 30 years and over: record linkage studies. Diabetologia. 2010;54(3):527-534. [DOI] [PubMed] [Google Scholar]
  • 22.Leitner BP, Siebel S, Akingbesote ND, Zhang X, Perry RJ. Insulin and cancer: a tangled web. Biochem J. 2022;479:583-607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Home P. Insulin therapy and cancer. Diabetes Care. 2013;36(Suppl 2):S240-S244. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Vicentini M, Ballotari P, Venturelli F, et al. Impact of insulin therapies on cancer incidence in type 1 and type 2 diabetes: a population-based cohort study in Reggio Emilia, Italy. Cancers. 2022;14:2719. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Malmberg K, Ryden L, Wedel H, et al. FASTTRACK ´ intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J. 2005;26:650-661. [DOI] [PubMed] [Google Scholar]
  • 26.ORIGIN Trial Investigators. Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367:319-328. [DOI] [PubMed] [Google Scholar]
  • 27.Tang H, Yang K, Song Y, Han J. Meta‐analysis of the association between sodium‐glucose co‐transporter‐2 inhibitors and risk of skin cancer among patients with type 2 diabetes. Diabetes Obes Metab. 2018;20(12):2919-2924. [DOI] [PubMed] [Google Scholar]
  • 28.Tseng C-H. Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese. BMC Cancer. 2015;15(1):41. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Tseng C-H. Metformin is associated with decreased skin cancer risk in Taiwanese patients with type 2 diabetes. J Am Acad Dermatol. 2018;78(4):694-700. [DOI] [PubMed] [Google Scholar]
  • 30.Chuang TY, Lewis DA, Spandau DF. Decreased incidence of nonmelanoma skin cancer in patients with type 2 diabetes mellitus using insulin: a pilot study. Br J Dermatol. 2005;153(3):552-557. [DOI] [PubMed] [Google Scholar]
  • 31.Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health. 2010;100(Suppl 1):S186-196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Braveman P, Gottlieb L. The social determinants of health: it’s time to consider the causes of the causes. Public Health Rep. 2014;129(Suppl 2):19-31. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Marmot M, Bell R. Social determinants and non-communicable diseases: time for integrated action. BMJ. 2019;364:l251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol. 2006;55(5):741-760. [DOI] [PubMed] [Google Scholar]
  • 35.Padovese V, Franco G, Valenzano M, Pecoraro L, Cammilli M, Petrelli A. Skin cancer risk assessment in dark skinned immigrants: the role of social determinants and ethnicity. Ethn Health. 2018;23(6):649-658. [DOI] [PubMed] [Google Scholar]
  • 36.CDC . 2020 BRFSS survey data and documentation. 2021; https://www.cdc.gov/brfss/annual_data/annual_2020.html. Accessed April 11, 2022.
  • 37.Bursac Z, Gauss CH, Williams DK, Hosmer DW. Purposeful selection of variables in logistic regression. Source Code Biol Med. 2008;3(1):17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Mickey RM, Greenland S. The impact of confounder selection criteria on effect estimation. Am J Epidemiol. 1989;129(1):125-137. [DOI] [PubMed] [Google Scholar]
  • 39.Karlin NJ, Mangold AR, Amin SB, et al. Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. Future Sci OA. 2019;5(3):FSO368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Zhao L, Li Y, Qingbo L, et al. Insulin-attenuated inflammatory response of dendritic cells in diabetes by regulating RAGE-PKCβ1-IRS1-NF-κB signal pathway: a study on the anti-inflammatory mechanism of insulin in diabetes. J Diabetes Res. 2020;2020:1. [Google Scholar]
  • 41.Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology. 2012;143:390-399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Hill-Briggs F, Adler NE, Berkowitz SA, et al. Social determinants of health and diabetes: a scientific review. Diabetes Care. 2021;44:258-279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Ahn N, Jimeno JF, Ugidos A. ‘Mondays in the sun:’ unemployment, time use, and consumption patterns in Spain. Contrib Econ Anal. 2004;271:237-259. [Google Scholar]
  • 44.Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin Med J (Engl). 2022;135(5):584-590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008;88(11):1254-1264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Harvey VM, Patel H, Sandhu S, Wallington SF, Hinds G. Social determinants of racial and ethnic disparities in cutaneous melanoma outcomes. Cancer Control. 2014;21(4):343-349. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.McDaniel JT, Nuhu K, Ruiz J, Alorbi G. Social determinants of cancer incidence and mortality around the world: an ecological study. Global Health Promot. 2019;26(1):41-49. [DOI] [PubMed] [Google Scholar]
  • 48.Pollitt RA, Swetter SM, Johnson TM, Patil P, Geller AC. Examining the pathways linking lower socioeconomic status and advanced melanoma. Cancer. 2012;118(16):4004-4013. [DOI] [PubMed] [Google Scholar]
  • 49.Buster KJ, You Z, Fouad M, Elmets C. Skin cancer risk perceptions: a comparison across ethnicity, age, education, gender, and income. J Am Acad Dermatol. 2012;66(5):771-779. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Singh GK, Jemal A. Socioeconomic and racial/ethnic disparities in cancer mortality, incidence, and survival in the United States, 1950-2014: over six decades of changing patterns and widening inequalities. J Environ Public Health. 2017;2017:2819372. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Reyes-Ortiz CA, Goodwin JS, Zhang DD, Freeman JL. Socioeconomic status and chemotherapy use for melanoma in older people. Can J Aging. 2011;30(1):143-153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Reyes-Ortiz CA, Goodwin JS, Freeman JL, Kuo YF. Socioeconomic status and survival in older patients with melanoma. J Am Geriatr Soc. 2006;54(11):1758-1764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Walsh B, Silles M, O'Neill C. The role of private medical insurance in socio-economic inequalities in cancer screening uptake in Ireland. Health Econ. 2012;21(10):1250-1256. [DOI] [PubMed] [Google Scholar]
  • 54.Cormier JN, Xing Y, Ding M, et al. Ethnic differences among patients with cutaneous melanoma. Arch Intern Med. 2006;166(17):1907-1914. [DOI] [PubMed] [Google Scholar]
  • 55.Friedman LC, Bruce S, Weinberg AD, Cooper HP, Yen AH, Hill M. Early detection of skin cancer: racial/ethnic differences in behaviors and attitudes. J Cancer Educ. 1994;9(2):105-110. [DOI] [PubMed] [Google Scholar]
  • 56.Hill-Briggs F, Fitzpatrick SL. Overview of social determinants of health in the development of diabetes. Diabetes Care. 2023;46:1590-1598. [DOI] [PubMed] [Google Scholar]
  • 57.Walker RJ, Garacci E, Palatnik A, Ozieh MN, Egede LE. The longitudinal influence of social determinants of health on glycemic control in elderly adults with diabetes. Diabetes Care. 2020;43:759-766. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Isaacs D, Bellini NJ, Biba U, Cai A, Close KL. Health care disparities in use of continuous glucose monitoring. Diabetes Technol Ther. 2021;23(S3):S81-S87. [DOI] [PubMed] [Google Scholar]
  • 59.Tisnado DM, Adams JL, Liu H, et al. What is the concordance between the medical record and patient self-report as data sources for ambulatory care? Med Care. 2006;44(2):132-140. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplemental Material - Role of Insulin Use and Social Determinants of Health on Non-melanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System

Supplemental Material for Role of Insulin Use and Social Determinants of Health on Non-melanoma Skin Cancer: Results From the Behavioral Risk Factor Surveillance System by Nour Massouh, Ayad A. Jaffa, and Miran A. Jaffa in Cancer Control

Data Availability Statement

The dataset supporting the conclusions of this article is available on the CDC website, https://www.cdc.gov/brfss/annual_data/annual_2020.html.


Articles from Cancer Control : Journal of the Moffitt Cancer Center are provided here courtesy of SAGE Publications

RESOURCES